Terminal cancer illness: strategies and management

  • V. A. Paladini
  • B. Barbolan
  • L. Di Bello
  • A. Zamperoni
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)


There is a relation between the way we live and the way we die. Each individual lives his or her life in a different way, with his/her own limits, disease, suffering and death. Each life is unique: the history of an individual with his/her family, socio-economic conditions, religion, spirituality, ethnic and racial background.


Neuropathic Pain Cancer Pain Analgesic Action Analgesic Efficacy Oral Morphine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Meier DE, Emmons CA, Wallenstein S et al (1998) A national survey of physician-assisted suicide and euthanasia in United States. N Engl J Med 338: 1193–1201PubMedCrossRefGoogle Scholar
  2. 2.
    Asai A, Fukuhara S, Lo B (1995) Attitudes of Japanese and Japanese-American physicians towards life-sustaining treatment. Lancet 346: 356–359PubMedCrossRefGoogle Scholar
  3. 3.
    Tanida N (1995) Commentary on attitudes of Japanese physicians towards life-sustaining treatment. Lancet 346: 970–971PubMedCrossRefGoogle Scholar
  4. 4.
    Sgreccia E (1992) Linee etiche per l’assistenza medica al malato terminale. Min Anestesiol 58: 581–585Google Scholar
  5. 5.
    Paladini VA, Peressin P, Contin F (1990) Principi di terapia dei sintomi nel cancro avanzato. Gi Med Crit Ter Antalg e Cure Palliative 2: 26–31Google Scholar
  6. 6.
    Paladini VA, Peressin P, Comm F (1990) Psicosi nel paziente con cancro avanzato: diagnostica e Terapia. Gi Med Crit Ter Antalg Cure Palliative 2: 32–38Google Scholar
  7. 7.
    Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA (1996) Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 64: 107–114PubMedCrossRefGoogle Scholar
  8. 8.
    McQuay HJ (1997) Opioid use in cancer pain. Acta Anaesthesiol Scand 41: 175–183PubMedCrossRefGoogle Scholar
  9. 9.
    Twycross R (1997) Cancer pain classification. Acta Anaesthesiol Scand 41: 141–145PubMedCrossRefGoogle Scholar
  10. 10.
    Xu XJ, Puke MJC, Verge VMK et al (1993) Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett 152: 129–132PubMedCrossRefGoogle Scholar
  11. 11.
    Xu XJ, Wiesenfeld-Hallin Z (1991) The threshold for the depressive effect of intrathecal morphine on the spinal nociceptive flexor reflex is increased during autotomy after sciatic nerve section in rats. Pain 46: 223–229PubMedCrossRefGoogle Scholar
  12. 12.
    Zech DFJ, Grond S, Lynch J et al (1995) Validation of World Health Organisation guidelines for cancer pain relief: a 10-year prospective study. Pain 63: 65–76PubMedCrossRefGoogle Scholar
  13. 13.
    Paladini VA, Antonaglia V, Scalia M et al (1986) Pharmacological therapy in advanced cancer pain. In: Gullo A (ed) APICE. Trieste, p 34Google Scholar
  14. 14.
    Levy MH (1996) Pharmacologic treatment of cancer pain. N Engl J Med 335: 1124–1132PubMedCrossRefGoogle Scholar
  15. 15.
    Driessen B (1992) Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain, in vitro. Br J Pharmacol 105: 147–151.PubMedGoogle Scholar
  16. 17.
    Tawfik MO (1990) Tramadol hydrochloride in the relief of cancer pain: a double-blind comparison against sustained release morphine. Pain 8 (Suppl 5): 377CrossRefGoogle Scholar
  17. 18.
    Christrup LL (1997) Morphine metabolites. Acta Anaesthesiol Scand 41: 116–122PubMedCrossRefGoogle Scholar
  18. 19.
    De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10: 378–384PubMedCrossRefGoogle Scholar
  19. 20.
    Paladini VA, Mocavero G, Saltarim M et al (1990) Livelli ematici ed analgesia della morfina a lento rilascio nel dolore da cancro. G Med Crit Ter Antalg Cure Palliative 2: 39–48Google Scholar
  20. 21.
    Gourlay G, Cherry D, Cousins M (1986) A comparative study of the efficacy of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25: 297–312PubMedCrossRefGoogle Scholar
  21. 23.
    Paul D, Standifer K, Inturrisi C, Pasternak G (1989) Pharmacological characterization of morphine-6beta-glucoronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251: 477–483PubMedGoogle Scholar
  22. 24.
    Mocavero G (1986) Techniques and results of the injection of opioids into the cerebral ventricle through a cervical catheter. In: Gullo A (ed) Advances in Anaesthesia, Intensive Care and Pain Therapy Postgraduate Course. Trieste, p 71Google Scholar
  23. 25.
    Bell MDD, Mishra P, Weldon BD, Murray GR, Calvey TN, Williams NE (1985) Buccal morphine — a new route for analgesia? Lancet 1: 71PubMedCrossRefGoogle Scholar
  24. 26.
    Mocavero G (1989) Le nuove tecniche in terapia antalgica. La somatostatina, la morfina e la lidocaina somministrate mediante aerosol nasale, instillazione oculare e sul ganglio sfeno-palatino danno analgesia. G Med Grit Ter Antalg Cure Palliative 1: 190–193Google Scholar
  25. 27.
    Mocavero G (1981) Analgesia selettiva con morfina perinervosa. Incontri di Anestesia, Rianimazione e Scienze Affini 16: 1–3Google Scholar
  26. 28.
    Krajnik M, Zyhcz Z (1997) Topical morphine in malignant cutaneous pain. Abstracts of the Fifth Congress of the European Association for Palliative Care, London, p S34Google Scholar
  27. 29.
    Portenoy RK, Southam MA, Gupta SK et al (1993) Transdermal fentanyl for cancer pain Anaesthesiology 78: 36–43Google Scholar
  28. 30.
    Holley FO, van Steennis C (1988) Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i v. and transdermal delivery. Br J Anaesth 60: 608–613PubMedCrossRefGoogle Scholar
  29. 31.
    Plezia PM, Kramer TH, Linford J, Hameroff SR (1989) Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy 9: 2–9PubMedGoogle Scholar
  30. 32.
    Gourlay GK, Kowalski SR, Plummer JL et al (1989) The transdermal administration of fentanyl in the treatment of postoperative pain. Pain 37: 193–202PubMedCrossRefGoogle Scholar
  31. 33.
    Korte W, de Stoutz N, Morant R (1996) Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short-and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 11: 139–146PubMedCrossRefGoogle Scholar
  32. 34.
    Dellemiln R, Vanneste JAL (1997) Randomized double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 345: 753–758CrossRefGoogle Scholar
  33. 35.
    McDonald CJ, Miller AJ (1997) A comparative potency study of a controlled release tablet formulation of hydromorphone with controlled release morphine in patients with cancer pain. Abstracts of the Fifth Congress of the European Association for Palliative Care, London, September, p S37Google Scholar
  34. 36.
    Heiskanan TY, Kalso E,(1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73: 37–45CrossRefGoogle Scholar
  35. 37.
    Sacerdote P, Bianchi M, Manfredi B et al (1997) Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 72: 325–330PubMedCrossRefGoogle Scholar
  36. 38.
    Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs• a structure-related activity study. Br J Pharmacol 121: 834–840PubMedCrossRefGoogle Scholar
  37. 39.
    Agency for Health Care Policy and Research (1994) New clinical-practice guidelines for the management of pain in patient with cancer. N Engl J Med 3: 651–655Google Scholar
  38. 40.
    Ahmedzai S (1997) Pain control in patients with cancer. Eur J Cancer 33: S55 - S62CrossRefGoogle Scholar
  39. 41.
    Grond S, Zech D, Schug SA, Lynch J, Lehmann KA (1991) The importance of non-opioid analgesics for cancer pain relief according to guidelines of the World Health Organization. Int J Clin Pharmacol Res 11: 253–260PubMedGoogle Scholar
  40. 42.
    Bonica JJ, Ventafridda V (1979) Advances in pain research and therapy. Raven, New York, pp 255–262Google Scholar
  41. 43.
    American Society of Anaesthesiologists Task Force on Pain Management, Cancer Pain Section (1996) Practice guideliness for cancer pain management. Anaesthesiology 84: 1243–1257CrossRefGoogle Scholar
  42. 44.
    Payne R (1997) Mechanism and management of bone pain. Cancer 80: S1608 - S1612CrossRefGoogle Scholar
  43. 45.
    Portenoy RK (1992) Cancer pain: pathophysiology and syndromes. Lancet 339: 10261035CrossRefGoogle Scholar
  44. 46.
    Eisemberg S, Berkey CS, Carr DB (1994) Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12: 2756–2765Google Scholar
  45. 47.
    Farhat F, Savoyen MC, Jair C (1995) Efficacité du propacetamol sur la doleur postoperatoire selon deux modés d’administration intraveineuse. Cab Anaesthesiol 43: 351–356Google Scholar
  46. 48.
    Friedel HA (1993) Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 45: 131–156PubMedCrossRefGoogle Scholar
  47. 49.
    Engelhardt G (1996) Pharmacology of meloxicam, a new nonsteroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Rheumatology 35 (Suppl 1): 4–12CrossRefGoogle Scholar
  48. 50.
    Markham A, Bryson HM (1995) Deflazacort. A rewiew of its pharmacological properties and therapeutic efficacy. Drugs 50: 317–333Google Scholar
  49. 51.
    Yeomans ND, Tulassay Z, Juhasz L et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 338: 719–726PubMedCrossRefGoogle Scholar
  50. 52.
    Hawkey KJ, Karrash JA, Szczepanski L (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 727734 338:Google Scholar
  51. 53.
    Twycross RG (1993) Advances in cancer pain management. J Pharmacol Care Pain Symptom Control 1: 5–30CrossRefGoogle Scholar
  52. 56.
    Galer BS Treatment of neuropathic pain: use of “adjuvant” analgesic. Vol 122. American Academy of Neurology, 49th Annual Meeting pp 43–47Google Scholar
  53. 57.
    Shima Y, Yanagisawa H, Aruga E (1997) Neuropathic pain: treatment with low dose ketamine. Abstracts of the Fifth Congress of the European Association for Palliative Care, London, p S32Google Scholar
  54. 58.
    Dickenson AH (1997) NMDA receptor antagonists; interaction with opioids. Acta Anaesth Scand 41: 112–115PubMedCrossRefGoogle Scholar
  55. 59.
    Arné S, Meyerson BA (1998) Lack of analgesic effects of opioids on neuropathic pain and idiopathic forms of pain. Pain 33: 11–23CrossRefGoogle Scholar
  56. 60.
    Sacerdote P, Brini A, Mantegazza P, Panerai AE (1987) A role for serotonin and beta-endorphine in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol Biochem Behav 26: 153PubMedCrossRefGoogle Scholar
  57. 61.
    Panerai AE (1988) Il concetto di potenziamento in farmacologia. Min Anestesiol 54: 123Google Scholar
  58. 62.
    Panerai AE, Bianchi M (1966) Farmacologia degli analgesici: gli antidepressivi, nuovi aspetti del loro meccanismo d’azione. Proceedings 18° Congresso Nazionale Associazione Italiana per lo Studio del Dolore (AISD), pp 55–58Google Scholar
  59. 63.
    Sacerdote P, Bianchi M, Panerai AE (1997) In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat. Eur J Pharmacol 319: 287–290PubMedCrossRefGoogle Scholar
  60. 64.
    McQuay HJ (1977) Antidepressants and chronic pain. Br Med J 314: 763–765CrossRefGoogle Scholar
  61. 65.
    Walsh TD (1983) Review. Antidepressants in chronic pain. Clin Neuropharmacol 6:271 66 Bianchi M, Rossom G, Sacerdote P, Panerai AE, Berti F (1995) Carbamazepme exerts anti-inflammatory effects in the rat. Eur J Pharmacol 294: 71–74Google Scholar
  62. 67.
    Taylor CP (1995) Gabapentin: mechanisms of action. In: Levy RH et al (eds) Antiepilectic drugs. Raven, New York, pp 829–841Google Scholar
  63. 68.
    Backonja M, Hes MS, La Moreaux LK, Garofalo EE, Koto EM (1997) Gabapentin (neurontin) reduces pain in diabetics patients with painful peripheral neuropathics: results of a double-blind placebo controlled clinical trial. American Pain Society, 16th Annual Scientific Meeting Program Book, p 108Google Scholar
  64. 69.
    Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl Med 335: 1785–1791CrossRefGoogle Scholar
  65. 70.
    Lipton A,Glover D, Harvey H et al (1994) Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann On-col 5 (Suppl 7): S31–35Google Scholar
  66. 71.
    O’Rourke N, MacCloskey E, Houghton F et al (1995) Double-blind, placebo-controlled trial of oral clodronate in patients with bone metastases J Clin Oncol 13: 929–934Google Scholar
  67. 72.
    Blake G (1986) Strontium-89 therapy: strontium kinetics in dissemination carcinoma of the prostate. Eur J Nucl Med 12: 447–454PubMedGoogle Scholar
  68. 73.
    Foley KM (1985) The treatment of cancer pain. N Engl J Med 11: 84–95CrossRefGoogle Scholar
  69. 75.
    Olivo R, Paladini VA, Perotto A et al (1988) L’assistenza domiciliare al malato con dolore da cancro. Assistenza infermieristica. Recent Advances in Anaesthesia, Intensive Care and Pain Therapy Postgraduate Course. Trieste, pp 343–348Google Scholar
  70. 76.
    Ashby M, Stoffel B (1995) Artificial hydration and alimentation at the end of life: a reply to Craig. J Med Ethics 21: 135–140PubMedCrossRefGoogle Scholar
  71. 78.
    Margaret O, Paladini VA, luretigh C (1992) Anamnesi, valutazione, fabbisogni e principi terapeutici in terapia del dolore e cure palliative. II Corso residenziale a cura di Paladini VA, APICE. Trieste, pp 302–316Google Scholar
  72. 79.
    Paladini VA, Margarit O, Lugnani F (1996) La nutrizione domiciliare nella fase avanzata della malattia neoplastica: organizzazione dell’équipe di cura. In: Paladini VA (ed) La nutrizione domiciliare nel paziente con cancro avanzato. APICE. Trieste, pp 1–6Google Scholar
  73. 80.
    Bozzetti F (1996) Guidelines on artificial nutrition versus hydration in terminal cancer patient. Nutrition 12: 163–167PubMedCrossRefGoogle Scholar
  74. 81.
    McCann RM, Hall WJ, Gruth-Juncker A (1994) Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 272: 1263–1266Google Scholar
  75. 82.
    Ellershow JE, Sutcliffe JM, Saunders CM (1995) Dehydration and the dying patient. J Pain Symptom Manage 10: 221–228Google Scholar
  76. 83.
    Dunphy K, Finlay I, Rothbone G, Gilbert J, Hicks F (1995) Rehydration in palliative and terminal care: if not-why not? Palliat Med J 9: 221–228CrossRefGoogle Scholar
  77. 84.
    Dunlop RJ, Ellershow JE, Baines MJ et al (1995) On withholding nutrition and hydration in the terminally ill: has palliative medicine gone too far? A reply. J Med Ethics 21: 141–143PubMedCrossRefGoogle Scholar
  78. 85.
    Paladini VA, Margarit O, Lugnani F (1996) La nutrizione integrativa di supporto, per via orale, nel cancro avanzato. In: Gullo A (ed) La nutrizione domiciliare nel paziente con cancro avanzato. APICE. Trieste, pp 51–63Google Scholar
  79. 86.
    Paladini VA, Mocavero G (1993) Psicologia del dolore. Trattato enciclopedico di anestesiologia, rianimazione, terapia intensiva. In: Bellucci G, Damia G, Gasparetto A (eds) Terapia antalgica. Vol. 5. Piccin Nuove Librerie, Padova, pp 1–16Google Scholar
  80. 88.
    Paladini VA (1998) Principi di psicologia e psicoterapia del dolore cronico. In: Tiengo M (ed) II Corso Superiore di aggiornamento in fisiopatologia e terapia del dolore. Milano, pp 125–145Google Scholar
  81. 89.
    Paladini VA, Cusin SG, Cattaruzza I et al (1985) Dolore cronico e angoscia di morte attraverso il Rorschach. Min Anestesiol 51: 557–559Google Scholar
  82. 90.
    Paladini VA, Cusin SG, Cattaruzza I et al (1986) Ansia e depressione nel dolore cronico. Min Anestesiol 52: 321–324Google Scholar
  83. 91.
    Donner B, Zeus M, Tryba M et al (1996) Direct conversion from oral Morphine to trans-dermal fentanyl: a multicenter study in patients with cancer pain. Pain 64: 528CrossRefGoogle Scholar

Copyright information

© Springer Verlag Italia, Milano 1999

Authors and Affiliations

  • V. A. Paladini
  • B. Barbolan
  • L. Di Bello
  • A. Zamperoni

There are no affiliations available

Personalised recommendations